耐碳青霉烯类革兰阴性菌感染的治疗药物与联合抗菌策略进展  

Progress of study on drug therapy and combined antimicrobial strategy for carbapenem-resistant gram-negative bacteria infections

作　　者：吴俊[1] 赵子文[2] 

机构地区：[1]马鞍山市人民医院呼吸科,安徽马鞍山243000 [2]广州医科大学附属广州市第一人民医院呼吸科,广东广州510180

出　　处：《中华医院感染学杂志》2016年第9期2152-2156,共5页Chinese Journal of Nosocomiology

基　　金：广东省自然科学基金资助项目(10151006001000015);马鞍山市科技计划基金资助项目(YL-2015-05)

摘　　要：革兰阴性菌是医院感染常见病原菌,近年来,随着大量抗菌药物广泛使用,革兰阴性菌耐药性日趋严重,甚至出现了泛耐药菌;碳青霉烯类抗菌药亦失去"最后一道防线"地位,出现了耐碳青霉烯类革兰阴性菌,因治疗药物极其有限,对抗感染治疗构成极大威胁;因此该综述以肠杆菌科细菌、非发酵革兰阴性菌为代表,对近年来常见耐碳青霉烯类革兰阴性菌的治疗药物及联合治疗策略进展进行总结,为临床治疗提供参考。Gram-negative bacteria are the common pathogens causing nosocomial infections.With the extensive use of antibacterial drugs,the drug resistance of the gram-negative bacteria has become increasingly serious in recent years,and even the pandrug-resistant strains have emerged.Carbapenems antibiotics were no longer the last line of defense,and the carbapenem-resistant gram-negative bacteria have emerged,which posed great threat to the antiinfection treatment due to the limited use of drugs.The review summarizes the drug therapy and combined antimicrobial strategy for the carbapenem-resistant gram-negative bacteria in recent years,represented by Enterobacteriaceae and non-fermenting gram-negative bacteria,so as to provide guidance for clinical treatment.

关 键 词：碳青霉烯类 革兰阴性菌 治疗 

分 类 号：R378[医药卫生—病原生物学]